The Role of NLR-related Protein 3 Inflammasome in Host Defense and Inflammatory Diseases

키워드

참고문헌 (94)

1. Palm NW, "Pattern recognition receptors and control of adaptive immunity", Immunol Rev, 227, pp.221~233 (2009)
2. Akira S, "Innate immunity and adjuvants", Philos Trans R Soc Lond B Biol Sci, 366, pp.2748~2755 (2011)
3. Latz E, "The inflammasomes: mechanisms of activation and function", Curr Opin Immunol, 22, pp.28~33 (2010)
4. Strowig T, "Inflammasomes in health and disease", Nature, 481, pp.278~286 (2012)
5. Masters SL, "Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*)", Annu Rev Immunol, 27, pp.621~668 (2009)
6. Agostini L, "NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder", Immunity, 20, pp.319~325 (2004)
7. Lamkanfi M, "The inflammasomes", PLoS Pathog, 5, pp.e1000510~ (2009)
8. Kanneganti TD, "Critical role for Cryopyrin", Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA, 2006, pp.281, 36560~36568
9. Mariathasan S, "Cryopyrin activates the inflammasome in response to toxins and ATP", Nature, 440, pp.228~232 (2006)
10. Martinon F, "Gout-associated uric acid crystals activate the NALP3 inflammasome", Nature, 440, pp.237~241 (2006)
11. Sutterwala FS, "Critical role for NALP3", CIAS1, Immunity, pp.2006, 24[DOI]
12. De Nardo D, "NLRP3 inflammasomes link inflammation and metabolic disease", Trends Immunol, 32, pp.373~379 (2011)
13. Schroder K, "The NLRP3 inflammasome: a sensor for metabolic danger?", Science, 327, pp.296~300 (2010)
14. Franchi L, "Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages", Nat Immunol, 7, pp.576~582 (2006)
15. Gross O, "Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence", Nature, 459, pp.433~436 (2009)
16. Ghiringhelli F, "Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors", Nat Med, 15, pp.1170~1178 (2009)
17. Zhou R, "A role for mitochondria in NLRP3 inflammasome activation", Nature, 469, pp.221~225 (2011)
18. 이선진, "Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome", NATURE IMMUNOLOGY, 12(3), pp.222~57, NATURE PUBLISHING GROUP
19. Halle A, "The NALP3 inflammasome is involved in the innate immune response to amyloid-beta", Nat Immunol, 9, pp.857~865 (2008)
20. Hornung V, "Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization", Nat Immunol, 9, pp.847~856 (2008)
21. Pétrilli V, "Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration", Cell Death Differ, 14, pp.1583~1589 (2007)
22. Dinarello CA, "Interleukin-18 and host defense against infection", J Infect Dis, 187(Suppl 2), pp.S370~S384 (2003)
23. 찰스디나렐로, "Immunological and Inflammatory Functions of the Interleukin-1 Family", ANNUAL REVIEW OF IMMUNOLOGY, 27, pp.519~550 (2009), ANNUAL REVIEWS
24. Hise AG, "An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans", Cell Host Microbe, 5, pp.487~497 (2009)
25. Joly S, "Cutting edge: Candida albicans hyphae formation triggers activation of the Nlrp3 inflammasome", J Immunol, 183, pp.3578~3581 (2009)
26. 장명호, "Involvement of the NLRP3 Inflammasome in Innate and Humoral Adaptive Immune Responses to Fungal beta-Glucan", JOURNAL OF IMMUNOLOGY, 183(12), pp.8061~8067, AMER ASSOC IMMUNOLOGISTS
27. Saïd-Sadier N, "Aspergillus fumigatus stimulates the NLRP3 inflammasome through a pathway requiring ROS production and the Syk tyrosine kinase", PLoS One, 5, pp.e10008~ (2010)
28. Kankkunen P, "Matikainen S. (1,3)-beta-glucans activate both dectin-1 and NLRP3 inflammasome in human", J Immunol, 184, pp.6335~6342 (2010)
29. Craven RR, "Staphylococcus aureus alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells", PLoS One, 4, pp.e7446~ (2009)
30. 박종환, "Activation of the Nlrp3 Inflammasome by Streptococcus pyogenes Requires Streptolysin O and NF-kappa B Activation but Proceeds Independently of TLR Signaling and P2X7 Receptor", JOURNAL OF IMMUNOLOGY, 183(9), pp.5823~5829, AMER ASSOC IMMUNOLOGISTS
31. Toma C, "Pathogenic Vibrio activate NLRP3 inflammasome via cytotoxins and TLR", nucleotide-binding oligomerization domain-mediated NF-kappa B signaling, 2010, pp.184, 5287~5297
32. Miao EA, "Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf", Nat Immunol, 7, pp.569~575 (2006)
33. Broz P, "Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella", J Exp Med, 207, pp.1745~1755 (2010)
34. Ceballos-Olvera I, "Inflammasome-dependent pyroptosis and IL-18 protect against Burkholderia pseudomallei lung infection while IL-1β is deleterious", PLoS Pathog, 7, pp.1002452~ (2011)
35. Duncan JA, "Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASC-containing inflammasome", J Immunol, 182, pp.6460~6469 (2009)
36. Hvid M, "Interleukin-1 is the initiator of Fallopian tube destruction during Chlamydia trachomatis infection", Cell Microbiol, 9, pp.2795~2803 (2007)
37. Fernandes-Alnemri T, "The AIM2 inflammasome is critical for innate immunity to Francisella tularensis", Nat Immunol, 11, pp.385~393 (2010)
38. Atianand MK, "Francisella tularensis reveals a disparity between human and mouse NLRP3 inflammasome activation", J Biol Chem, 286, pp.39033~39042 (2011)
39. Master SS, "Mycobacterium tuberculosis prevents inflammasome activation", Cell Host Microbe, 3, pp.224~232 (2008)
40. Mishra BB, "Mycobacterium tuberculosis protein ESAT-6 is a potent activator of the NLRP3", ASC inflammasome, 2010, pp.12, 1046~1063
41. McElvania Tekippe E, "Granuloma formation and host defense in chronic Mycobacterium tuberculosis infection requires PYCARD", ASC but not NLRP3 or caspase-1, 2010, pp.5, e12320~
42. Dorhoi A, "Activation of the NLRP3 inflammasome by Mycobacterium tuberculosis is uncoupled from susceptibility to active tuberculosis", Eur J Immunol, 42, pp.374~384 (2012)
43. Wong KW, "Critical role for NLRP3 in necrotic death triggered by Mycobacterium tuberculosis", Cell Microbiol, 13, pp.1371~1384 (2011)
44. 이혜미, "Mycobacterium abscessus activates the NLRP3 inflammasome via Dectin-1-Syk and p62", SQSTM1, 2012, pp.90(6), 601~610[DOI]
45. Carlsson F, "Host-detrimental role of Esx-1-mediated inflammasome activation in mycobacterial infection", PLoS Pathog, 6, pp.e1000895~ (2010)
46. Rajan JV, "The NLRP3 inflammasome detects encephalomyocarditis virus and vesicular stomatitis virus infection", J Virol, 85, pp.4167~4172 (2011)
47. Poeck H, "Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production", Nat Immunol, 11, pp.63~69 (2010)
48. Segovia J, "TLR2", MyD88, ASC inflammasome during respiratory syncytial virus infection, pp.PLoS One, 2012[DOI]
49. Burdette D, "virus activates interleukin-1β via caspase-1-inflammasome complex", J Gen Virol, 93, pp.235~246 (2012)
50. Bürckstümmer T, "An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome", Nat Immunol, 10, pp.266~272 (2009)
51. Nour AM, "Varicella-zoster virus infection triggers formation of an interleukin-1β (IL-1β)-processing inflammasome complex", J Biol Chem, 286, pp.17921~17933 (2011)
52. Delaloye J, "Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome", PLoS Pathog, 5, pp.e1000480~ (2009)
53. Pontillo A, "A 3’UTR SNP in NLRP3 gene is associated with susceptibility to HIV-1 infection", J Acquir Immune Defic Syndr, 54, pp.236~240 (2010)
54. Hoffman HM, "Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome", Nat Genet, 29, pp.301~305 (2001)
55. Feldmann J, "Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes", Am J Hum Genet, 71, pp.198~203 (2002)
56. Dowds TA, "Cryopyrin-induced interleukin 1beta secretion in monocytic cells: enhanced activity of disease-associated mutants and requirement for ASC", J Biol Chem, 279, pp.21924~21928 (2004)
57. Spilberg I., "Current concepts of the mechanism of acute inflammation in gouty arthritis", Arthritis Rheum, 18, pp.129~134 (1975)
58. Martin WJ, "Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout", Arthritis Rheum, 60, pp.281~289 (2009)
59. Torres R, "Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis", Ann Rheum Dis, 68, pp.1602~1608 (2009)
60. McGonagle D, "Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra", Ann Rheum Dis, 66, pp.1683~1684 (2007)
61. So A, "A pilot study of IL-1 inhibition by anakinra in acute gout", Arthritis Res Ther, 9, pp.R28~ (2007)
62. Gasse P, "Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis", Am J Respir Crit Care Med, 179, pp.903~913 (2009)
63. Ross R., "Atherosclerosis: an inflammatory disease", N Engl J Med, 340, pp.115~126 (1999)
64. Mizuno Y, "Inflammation and the development of atherosclerosis", J Atheroscler Thromb, 18, pp.351~358 (2011)
65. Abela GS, "Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation", J Clin Lipidol, 4, pp.156~164 (2010)
66. Espinola-Klein C, "Inflammatory markers and cardiovascular risk in the metabolic syndrome", Front Biosci, 16, pp.1663~1674 (2011)
67. He X, "Inflammation and fibrosis during Chlamydia pneumoniae infection is regulated by IL-1 and the NLRP3", ASC inflammasome, 2010, pp.184, 5743~5754
68. Duewell P, "NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals", Nature, 464, pp.1357~1361 (2010)
69. Rajamäki K, "Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation", PLoS One, 5, pp.e11765~ (2010)
70. Kahn SE, "Mechanisms linking obesity to insulin resistance and type 2 diabetes", Nature, 444, pp.840~846 (2006)
71. Spranger J, "Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study", Diabetes, 52, pp.812~817 (2003)
72. Thorand B, "Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA", KORA Augsburg Study, 1984-2002, 2005, pp.54, 2932~2938
73. Bendtzen K, "Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans", Science, 232, pp.1545~1547 (1986)
74. Böni-Schnetzler M, "Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I", Endocrinology, 150, pp.5218~5229 (2009)
75. Maedler K, "Interleukin-1 beta targeted therapy for type 2 diabetes", Expert Opin Biol Ther, 9, pp.1177~1188 (2009)
76. Ehses JA, "IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat", Proc Natl Acad Sci U S A, 106, pp.13998~14003 (2009)
77. Donath MY, "Type 2 diabetes as an inflammatory disease", Nat Rev Immunol, 11, pp.98~107 (2011)
78. Cooper GJ, "Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients", Proc Natl Acad Sci U S A, 84, pp.8628~8632 (1987)
79. Masters SL, "Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes", Nat Immunol, 11, pp.897~904 (2010)
80. Westwell-Roper C, "IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction", J Immunol, 187, pp.2755~2765 (2011)
81. 최인표, "Thioredoxin-interacting protein links oxidative stress to inflammasome activation", NATURE IMMUNOLOGY, 11, pp.136~U51, NATURE PUBLISHING GROUP
82. Chen J, "Lack of TXNIP protects against mitochondria-mediated apoptosis but not against fatty acid-induced ER stress-mediated beta-cell death", Diabetes, 59, pp.440~447 (2010)
83. Komura T, "CD14+ monocytes are vulnerable and functionally impaired under endoplasmic reticulum stress in patients with type 2 diabetes", Diabetes, 59, pp.634~643 (2010)
84. Menu P, "ER stress activates the NLRP3 inflammasome via an UPR-independent pathway", Cell Death Dis, 3, pp.e261~ (2012)
85. Bresnihan B., "Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist", Ann Rheum Dis, 58(Suppl 1), pp.I96~I98 (1999)
86. Hawkins PN, "Interleukin-1-receptor antagonist in the Muckle-Wells syndrome", N Engl J Med, 348, pp.2583~2584 (2003)
87. Hoffman HM, "Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist", Lancet, 364, pp.1779~1785 (2004)
88. Hoffman HM, "Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies", Arthritis Rheum, 58, pp.2443~2452 (2008)
89. Dalbeth N, "Gout in 2010: progress and controversies in treatment", Nat Rev Rheumatol, 7, pp.77~78 (2011)
90. Terkeltaub R, "The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study", Ann Rheum Dis, 68, pp.1613~1617 (2009)
91. So A, "Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study", Arthritis Rheum, 62, pp.3064~3076 (2010)
92. McGonagle D, "Successful treatment of resistant pseudogout with anakinra", Arthritis Rheum, 58, pp.631~633 (2008)
93. Stack JH, "IL-converting enzyme", caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients, 2005, pp.175, 2630~2634
94. Mitroulis I, "Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome", Eur J Intern Med, 21, pp.157~163 (2010)

관련 논문AI추천